The BARI 2D study: A randomised trial of therapies for type 2 diabetes and coronary artery disease

Martin Rutter; Martin K. Rutter; Richard W. Nesto

doi:10.1177/1479164109354145

The BARI 2D study: A randomised trial of therapies for type 2 diabetes and coronary artery disease

Martin Rutter, Martin K. Rutter, Richard W. Nesto

Research output: Contribution to journal › Article › peer-review

Abstract

The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomized 2368 patients with type 2 diabetes (T2DM) and coronary artery disease to either prompt revascularization or intensive medical therapy alone; and to either insulin-sensitization or insulin-provision diabetes therapy. Randomization was stratified by proposed revascularization method. Five-year survival and major cardiovascular events (MACE) were similar in study subgroups except in the coronary bypass surgery (CABG) stratum where there were fewer MACE after revascularization. There was less hypoglycaemia and weight gain, and greater apparent benefit from CABG in the insulin sensitization group. BARI 2D has provided important data for clinicians. © The Author(s) 2010.

Original language	English
Pages (from-to)	69-72
Number of pages	3
Journal	Diabetes and Vascular Disease Research
Volume	7
Issue number	1
DOIs	https://doi.org/10.1177/1479164109354145
Publication status	Published - 2010

Keywords

Coronary artery disease
Insulin
Revascularisation
Type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1479164109354145

Cite this

@article{6c13970e89344f9c88873d60d0dbcbf1,

title = "The BARI 2D study: A randomised trial of therapies for type 2 diabetes and coronary artery disease",

abstract = "The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomized 2368 patients with type 2 diabetes (T2DM) and coronary artery disease to either prompt revascularization or intensive medical therapy alone; and to either insulin-sensitization or insulin-provision diabetes therapy. Randomization was stratified by proposed revascularization method. Five-year survival and major cardiovascular events (MACE) were similar in study subgroups except in the coronary bypass surgery (CABG) stratum where there were fewer MACE after revascularization. There was less hypoglycaemia and weight gain, and greater apparent benefit from CABG in the insulin sensitization group. BARI 2D has provided important data for clinicians. {\textcopyright} The Author(s) 2010.",

keywords = "Coronary artery disease, Insulin, Revascularisation, Type 2 diabetes",

author = "Martin Rutter and Rutter, {Martin K.} and Nesto, {Richard W.}",

year = "2010",

doi = "10.1177/1479164109354145",

language = "English",

volume = "7",

pages = "69--72",

journal = "Diabetes and Vascular Disease Research",

issn = "1479-1641",

publisher = "Sage Publications Ltd",

number = "1",

}

TY - JOUR

T1 - The BARI 2D study: A randomised trial of therapies for type 2 diabetes and coronary artery disease

AU - Rutter, Martin

AU - Rutter, Martin K.

AU - Nesto, Richard W.

PY - 2010

Y1 - 2010

N2 - The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomized 2368 patients with type 2 diabetes (T2DM) and coronary artery disease to either prompt revascularization or intensive medical therapy alone; and to either insulin-sensitization or insulin-provision diabetes therapy. Randomization was stratified by proposed revascularization method. Five-year survival and major cardiovascular events (MACE) were similar in study subgroups except in the coronary bypass surgery (CABG) stratum where there were fewer MACE after revascularization. There was less hypoglycaemia and weight gain, and greater apparent benefit from CABG in the insulin sensitization group. BARI 2D has provided important data for clinicians. © The Author(s) 2010.

AB - The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomized 2368 patients with type 2 diabetes (T2DM) and coronary artery disease to either prompt revascularization or intensive medical therapy alone; and to either insulin-sensitization or insulin-provision diabetes therapy. Randomization was stratified by proposed revascularization method. Five-year survival and major cardiovascular events (MACE) were similar in study subgroups except in the coronary bypass surgery (CABG) stratum where there were fewer MACE after revascularization. There was less hypoglycaemia and weight gain, and greater apparent benefit from CABG in the insulin sensitization group. BARI 2D has provided important data for clinicians. © The Author(s) 2010.

KW - Coronary artery disease

KW - Insulin

KW - Revascularisation

KW - Type 2 diabetes

U2 - 10.1177/1479164109354145

DO - 10.1177/1479164109354145

M3 - Article

SN - 1479-1641

VL - 7

SP - 69

EP - 72

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

IS - 1

ER -

The BARI 2D study: A randomised trial of therapies for type 2 diabetes and coronary artery disease

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this